Supernus INDV
NASDAQ INDV
$36.25 +0.88 (+2.49%)
At close: Nov 2, 2026 · 4:00 PM EST

Supernus (INDV) EV to EBIT (2024 - 2026)

Updated

Indivior Pharmaceuticals' (INDV) EV to EBIT stood at 7.04 in Q3 2026, down 37.7% from 11.30 a year earlier and down 35.9% from the prior quarter.

Analysis

Supernus (INDV) EV to EBIT (2024 - 2026) Analysis & Trends

On a TTM basis, Indivior Pharmaceuticals' EV to EBIT came in at 5.97 as of Sep 30, 2026, down 0.4% year-over-year; for FY2025, it was 16.38, down 49.4% from FY2024.

  • Across earlier years, EV to EBIT came in at 32.35 in FY2024 and 6.62 in FY2021.
  • The Q3 2026 figure is the lowest quarterly EV to EBIT since Q2 2025.
  • On a year-over-year basis, EV to EBIT rose in 1 of the last four quarters, with an average decline of 17.1%.
  • Per Business Quant, the preceding three quarters came in at 10.97 (Q2 2026), 10.63 (Q1 2026) and 16.38 (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn
10 Supernus 4.28 Bn 3.38 Bn 305.00 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 7.04
Jun 30, 2026 10.97
Mar 31, 2026 10.63
Dec 31, 2025 16.38
Sep 30, 2025 11.30
Jun 30, 2025 6.07
Mar 31, 2025 28.14
Dec 31, 2024 32.35
API Access

Supernus EV to EBIT API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebit&ticker=INDV&period=max&api_key=YOUR_API_KEY